Repligen (RGEN) AI Stock Analysis

• Market Cap: $7.95B
• Dividend Yield: N/A
• Average Volume (3M): 907.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.34
• Revenue Growth: 4.88%
• EPS Growth: -196.93%
• Country: US
• Employees: 1,778
• Sector: Healthcare
• Sector Strength: 50
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.39
• Shares Outstanding: 56,183,100
• 10 Day Avg. Volume: 819,035
• 30 Day Avg. Volume: 907,290
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 26.15
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $238.21
• Price Target Upside: 93.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 17

Repligen's overall stock score reflects a balanced view of its current financial and market conditions. Strengths include a solid balance sheet and optimistic earnings guidance, contrasted by profitability challenges and technical indicators suggesting potential price pressure. Valuation remains a concern due to negative earnings and lack of dividend yield. The earnings call provides a positive outlook, mitigating some financial and valuation concerns. The overall score suggests caution with optimism for future growth.

Positive Factors

Financial Guidance

Repligen has favorably revised its top-line guidance for 2025 to a range of $695M to $720M, up from the prior $685-710M.

Revenue Growth

Repligen recorded 1Q25 revenue totaling $169.2M, slightly better than the original top-line forecast of $165M.

Negative Factors

Market and Economic Conditions

Uncertainty regarding current market and economic conditions, including tariff and Forex issues, is leading to a Hold rating on RGEN shares.

Net Earnings Guidance

Repligen expects full-year 2025 GAAP net earnings of $0.76 - $0.85 per diluted share, down from the original guidance range of $0.90 - $0.99 per diluted share.

Repligen Business Overview & Revenue Model

Company Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Repligen makes money by selling its bioprocessing products and services to biopharmaceutical companies and other entities involved in the production of biological drugs. The company's revenue model is primarily based on the sale of its filtration, chromatography, and analytics products, which are integral to the biomanufacturing process. Repligen's key revenue streams include direct product sales, service agreements, and licensing arrangements. The company also benefits from strategic partnerships and collaborations with leading biopharmaceutical firms, which help expand its market reach and enhance its technological capabilities. Additionally, Repligen invests in research and development to continuously innovate and improve its product offerings, further driving its revenue growth.

Repligen Financial Statement Overview

Summary

Repligen exhibits a mixed financial performance. The balance sheet is strong with low leverage and a high equity ratio, but profitability metrics are weak due to negative net income and EBIT margins. While operational cash flow is positive, free cash flow is declining, indicating potential financial instability.

Income Statement

Repligen's revenue shows a marginal growth from the previous year, but has declined from 2022. The gross profit margin for TTM is approximately 54.88%, indicating decent cost management. However, the company is experiencing negative net income and EBIT margins, highlighting profitability challenges. The EBITDA margin is positive at 13.80%, suggesting some operational efficiency.

Balance Sheet

The company's balance sheet is relatively strong with a debt-to-equity ratio of approximately 0.34, indicating low leverage. The equity ratio is around 69.60%, reflecting a healthy balance of equity financing. However, the return on equity is negative due to net losses, which is a concern for investors seeking returns.

Cash Flow

Repligen's cash flow statement shows a decrease in free cash flow compared to the annual report, with a negative free cash flow growth rate. The operating cash flow to net income ratio is negative due to the net loss, but operating cash flow remains positive, which indicates underlying operational strength despite profitability concerns.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
634.44M	632.36M	801.54M	670.53M	366.26M
	Gross Profit
274.64M	308.83M	455.71M	391.25M	209.63M
	EBIT
-35.11M	47.70M	133.61M	133.50M	42.54M
	EBITDA
82.10M	127.77M	246.93M	211.56M	101.62M
	Net Income Common Stockholders
-25.51M	35.60M	185.96M	128.29M	59.93M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
757.36M	751.32M	623.76M	603.81M	717.29M
	Total Assets
2.83B	2.83B	2.52B	2.36B	1.90B
	Total Debt
686.25M	711.80M	422.96M	366.05M	275.42M
	Net Debt
-71.11M	-39.52M	-100.50M	-237.76M	-441.88M
	Total Liabilities
856.95M	866.34M	613.96M	608.29M	373.74M
	Stockholders Equity
1.97B	1.97B	397.27M	1.75B	65.77M
Cash Flow		Free Cash Flow
142.49M	74.93M	38.74M	47.74M	36.28M
	Operating Cash Flow
175.39M	113.92M	172.08M	119.02M	62.63M
	Investing Cash Flow
-86.38M	-123.28M	-233.24M	-221.17M	-201.38M
	Financing Cash Flow
-82.90M	248.96M	-13.34M	961.00K	305.92M

Repligen Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 123.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGEN, the sentiment is Negative. The current price of 123.24 is below the 20-day moving average (MA) of 134.49, below the 50-day MA of 137.16, and below the 200-day MA of 146.18, indicating a bearish trend. The MACD of -1.44 indicates Positive momentum. The RSI at 39.31 is Neutral, neither overbought nor oversold. The STOCH value of 6.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RGEN.

Repligen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	70 Outperform	$5.49B	45.55	9.16%	―	8.24%	18.54%
STVN	67 Neutral	$5.80B	47.10	9.08%	0.25%	2.84%	-11.34%
TFX	58 Neutral	$5.33B	38.74	3.48%	1.08%	0.29%	-48.98%
ICUI	57 Neutral	$3.31B	―	-4.62%	―	7.19%	-56.19%
MASI	57 Neutral	$8.73B	116.65	-23.93%	―	-0.12%	-713.82%
RGEN	56 Neutral	$7.95B	―	-1.16%	―	4.88%	-196.93%
Sector *	52 Neutral	$5.17B	3.59	-42.19%	2.82%	15.05%	-0.04%

Repligen Corporate Events

Repligen Reports Strong Q3 2024 with Revenue Growth

Repligen Corporation reported a robust third quarter of 2024, with a 10% increase in revenue to $155 million year-over-year. The company experienced significant growth in the CDMO segment and equipment sales, each up by approximately 20%, and announced the acquisition of chromatography innovator Tantti Laboratory Inc. Repligen also opened a new Training and Innovation Center, enhancing its bioprocessing technology showcase. The adjusted net income reached $24 million, with a positive outlook for the upcoming year.